Harmony Biosciences (HRMY) Q1 2026 earnings review
Top-Line Growth Persists, But New Royalties Permanently Compress Margins
Harmony Biosciences delivered 17% YoY revenue growth for Q1 2026, keeping WAKIX on track for its $1.0B+ full-year target. However, the quality of earnings took a significant hit. Net Income fell 29% YoY to $32.5M, driven by a $32M upfront IPR&D charge for a novel amorphous pitolisant license. More concerningly, the newly signed Novitium license introduced new royalty obligations that structurally pushed Cost of Goods Sold (COGS) to 20.7% of revenue, up from 17.3% a year ago. While the pipeline—including Pitolisant GR/HD and the BP-205 orexin agonist—continues to mature, the aggressive pursuit of IP protection and licensing deals is actively eroding the company's previously pristine profitability profile.
🐂 Bull Case
Management confidently reiterated the $1.0B to $1.04B full-year 2026 net revenue guidance. Achieving this will solidify WAKIX as a blockbuster drug exclusively in narcolepsy.
The company is successfully stacking its catalyst calendar: Pitolisant GR NDA in Q2 2026, BP-205 Phase 1 PK data in mid-2026, and Pitolisant HD/EPX-100 Phase 3 data in 2027. The lifecycle plan to push IP protection into the 2040s is executing smoothly.
🐻 Bear Case
New royalties attached to the Novitium licensing agreement caused a 340-basis-point hit to gross margins. This is not a one-time item; it structurally reduces the profitability of the core franchise moving forward.
Operating Income fell sharply from $56.2M to $37.3M as the company relies heavily on expensive licensing (a $32M charge this quarter) to buy its way into post-2030 IP protection.
⚖️ Verdict: ⚪
Neutral. The pipeline is expanding and top-line demand for WAKIX remains resilient, but the sudden jump in COGS and steep sequential revenue drop flag that Harmony is paying an increasingly heavy price to maintain its growth trajectory.
Key Themes
Structural Gross Margin Compression Contradicts Bullish Narrative
While management highlighted a 17% YoY jump in WAKIX sales, they largely obscured a critical deterioration in unit economics. Cost of product sold (COGS) surged 39% YoY to $44.5M. As a percentage of revenue, COGS expanded from 17.3% in 25Q1 to 20.7% in 26Q1. This 340-bps gross margin compression was explicitly driven by new royalties related to the Novitium license agreement—meaning this is a permanent structural headwind, not a one-time charge.
Severe Sequential Revenue Deceleration
Despite maintaining its $1.0B+ 2026 guidance, Harmony posted a steep sequential revenue decline. WAKIX net revenue fell from $243.8M in 25Q4 to $215.4M in 26Q1. Management blamed 'market access headwinds observed every Q1', but an $28.4M quarter-over-quarter drop significantly breaks the momentum of the past three quarters. The average patient count (8,500) remained entirely flat from Q4.
Legal Whack-a-Mole Continues
Harmony has managed to settle with 6 of the 7 ANDA filers for the core WAKIX IP. However, securing the 2040s franchise extension required licensing a novel amorphous form of pitolisant from Novitium. Harmony immediately had to file a new patent infringement lawsuit in April against AET Pharma US and Sandoz over this exact newly acquired IP. The legal overhang remains a persistent drag on operating expenses.
Next-Generation Pitolisant Lifecycle Execution
The company is aggressively de-risking its post-2030 WAKIX cliff. Pitolisant GR (gastro-resistant) is on track for an NDA filing in Q2 2026, aimed at the 80-90% of narcolepsy patients who experience GI symptoms. Simultaneously, Pitolisant HD (high-dose, optimized PK) continues its Phase 3 ONSTRIDE trials, targeting differentiated labeling for fatigue and sleep inertia. Utility patents for these formulations push protection into the 2040s.
Orexin-2 Agonist (BP-205) Maturing
Harmony is advancing BP-205, positioning it as a best-in-class, highly potent Orexin-2 receptor agonist. The high potency is expected to enable significantly lower dosing than competitor assets, potentially allowing for a superior safety profile and once-daily dosing across NT1, NT2, and Idiopathic Hypersomnia. Phase 1 SAD/MAD clinical PK data is on track for mid-2026.
WAKIX Pediatric Cataplexy Approval
In February 2026, the FDA approved WAKIX for pediatric cataplexy. While the pediatric narcolepsy population is a smaller market segment, the commercial team initiated full promotional efforts immediately, providing incremental upside to the core franchise's 2026 growth trajectory.
Other KPIs
Reversing. Up 101% YoY from $34.5M in 25Q1. This massive acceleration was primarily driven by a $32.0 million upfront payment for new license agreements (including the novel amorphous pitolisant IP). This single charge stripped $0.45 per share from after-tax earnings.
Stable. Slightly down from $882.5M at the end of 2025. The reduction was directly attributed to the upfront payments for the new license agreements and cash payouts for the ANDA generic settlements. Despite this, the balance sheet remains exceptionally strong, supporting management's renewed focus on M&A targeting 2028-2032 revenue opportunities.
Guidance
Stable. The company reiterated its full-year revenue target. At the $1.02B midpoint, this implies approximately 17.5% YoY growth over FY25's $868M total. Given Q1 delivered 17% growth, the company will need steady performance across the remainder of the year to hit this landmark threshold.
Key Questions
Long-Term Gross Margin Target
With the new Novitium license agreement pushing Q1 COGS above 20% of revenue, should investors view ~80% gross margins as the permanent new baseline, or are there step-downs in the royalty structure at higher volume tiers?
Sequential Patient Additions
Average patient count for Q1 remained flat sequentially at 8,500. How much of the sequential drop in revenue was tied to actual prescription disruptions versus strictly Q1 gross-to-net accounting resets?
Amorphous Pitolisant Legal Threat
You just acquired the rights to the novel amorphous form of pitolisant and immediately filed suit against Sandoz and AET. What is the specific timeline and risk of an 'at-risk' generic launch regarding this specific patent prior to 2030?
BD Acquisition Sizing
With $870M in cash and a stated goal to acquire assets with revenue potential in the 2028-2032 timeframe, are you primarily looking at bolt-on acquisitions in the $100M-$300M range, or are you considering larger, transformational M&A that might require tapping debt markets?